Healthcare Industry News: CoNCERT Pharmaceuticals
News Release - April 16, 2008
CoNCERT Pharmaceuticals Announces Appointment of Justine Koenigsberg as Senior Director, Corporate Communications and Investor RelationsLEXINGTON, Mass.--(HSMN NewsFeed)--CoNCERT Pharmaceuticals, Inc., a company dedicated to creating safer, more effective medicines using precision deuterium chemistry, announced it has appointed Justine E. Koenigsberg Senior Director, Corporate Communications and Investor Relations. In this new position, she will be responsible for developing, implementing and managing CoNCERT’s external communications strategy including its investor relations efforts. She will report to CoNCERT’s Chief Operating Officer, Nancy Stuart.
“Justine is a seasoned investor relations professional and will play a critical role as we look to expand our visibility within the investment community,” said Roger Tung, Ph.D., President and Chief Executive Officer of CoNCERT Pharmaceuticals. “We are extremely pleased Justine is joining our management team and look forward to her contributions at CoNCERT.”
Ms. Koenigsberg has over twelve years corporate communications and investor relations experience within the biotechnology industry. She most recently served as Senior Director, Corporate Communications at ViaCell, Inc., which was acquired by PerkinElmer in November 2007. She joined ViaCell in September 2005 to establish the company's first internal corporate communications program. In this role she had overall responsibility for directing its external communications activities, including investor relations and public relations. Before joining ViaCell, Ms. Koenigsberg spent six years at Transkaryotic Therapies, Inc. (TKT), where she most recently served as Senior Director, Corporate Communications. During her tenure at TKT, she developed and implemented a variety of communication strategies and was involved in bringing closure to the company's $1.6 billion acquisition by Shire Pharmaceuticals Group plc. Prior to TKT, she worked in Corporate Communications at Vertex Pharmaceuticals Incorporated. Ms. Koenigsberg holds a Bachelor of Science degree in Business Administration from Northeastern University. She also serves on the Board of Directors of the Boston Chapter of the National Investor Relations Institute.
CoNCERT Pharmaceuticals, Inc. is dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. CoNCERT applies its innovative platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). CoNCERT leverages decades of pharmaceutical experience to create drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including hot flashes, fibrotic diseases, pain and infectious disease. CoNCERT expects to initiate its first clinical study in the second half of 2008. Additional information about CoNCERT is available online at http://www.concertpharma.com.
Source: CoNCERT Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.